Nov 16, 2021 / 09:40PM GMT
Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division - Director
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. I'm glad to have with us to close out the day, Exelixis, represented by Chris Senner, who is the Chief Financial Officer; and Andrew Peters, who heads up their business development efforts. I think normally, I would ask companies to make an opening statement with respect to who they are, what they do, but I'm pretty sure everyone knows who Exelixis is and what Exelixis does.
Questions and Answers:
Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division - DirectorSo maybe we can just kind of get right into the discussion here and start off by talking about the cabo launch into front-line RCC. I know that we're coming off sequentially down 3Q in terms of net sales. I know that demand metrics looked pretty strong. And obviously, your guidance suggests that that's not going to be the case again in 4Q. But what's your level
Trustpilot
